S&P 500   4,349.93 (-0.15%)
DOW   34,168.09 (-0.38%)
QQQ   344.57 (-0.16%)
AAPL   159.69 (-0.06%)
MSFT   296.71 (+2.85%)
FB   294.63 (-1.84%)
GOOGL   2,584.66 (+1.81%)
AMZN   2,777.45 (-0.80%)
TSLA   937.41 (+2.07%)
NVDA   227.72 (+2.01%)
BABA   113.37 (-4.84%)
NIO   22.66 (-4.75%)
AMD   110.71 (-0.38%)
CGC   7.23 (-1.77%)
MU   81.97 (+1.55%)
GE   89.32 (-1.96%)
T   24.25 (-8.42%)
F   19.91 (-0.35%)
DIS   133.60 (-2.13%)
AMC   15.94 (-0.50%)
PFE   53.01 (+0.89%)
ACB   4.06 (-3.56%)
BA   194.27 (-4.82%)
S&P 500   4,349.93 (-0.15%)
DOW   34,168.09 (-0.38%)
QQQ   344.57 (-0.16%)
AAPL   159.69 (-0.06%)
MSFT   296.71 (+2.85%)
FB   294.63 (-1.84%)
GOOGL   2,584.66 (+1.81%)
AMZN   2,777.45 (-0.80%)
TSLA   937.41 (+2.07%)
NVDA   227.72 (+2.01%)
BABA   113.37 (-4.84%)
NIO   22.66 (-4.75%)
AMD   110.71 (-0.38%)
CGC   7.23 (-1.77%)
MU   81.97 (+1.55%)
GE   89.32 (-1.96%)
T   24.25 (-8.42%)
F   19.91 (-0.35%)
DIS   133.60 (-2.13%)
AMC   15.94 (-0.50%)
PFE   53.01 (+0.89%)
ACB   4.06 (-3.56%)
BA   194.27 (-4.82%)
S&P 500   4,349.93 (-0.15%)
DOW   34,168.09 (-0.38%)
QQQ   344.57 (-0.16%)
AAPL   159.69 (-0.06%)
MSFT   296.71 (+2.85%)
FB   294.63 (-1.84%)
GOOGL   2,584.66 (+1.81%)
AMZN   2,777.45 (-0.80%)
TSLA   937.41 (+2.07%)
NVDA   227.72 (+2.01%)
BABA   113.37 (-4.84%)
NIO   22.66 (-4.75%)
AMD   110.71 (-0.38%)
CGC   7.23 (-1.77%)
MU   81.97 (+1.55%)
GE   89.32 (-1.96%)
T   24.25 (-8.42%)
F   19.91 (-0.35%)
DIS   133.60 (-2.13%)
AMC   15.94 (-0.50%)
PFE   53.01 (+0.89%)
ACB   4.06 (-3.56%)
BA   194.27 (-4.82%)
S&P 500   4,349.93 (-0.15%)
DOW   34,168.09 (-0.38%)
QQQ   344.57 (-0.16%)
AAPL   159.69 (-0.06%)
MSFT   296.71 (+2.85%)
FB   294.63 (-1.84%)
GOOGL   2,584.66 (+1.81%)
AMZN   2,777.45 (-0.80%)
TSLA   937.41 (+2.07%)
NVDA   227.72 (+2.01%)
BABA   113.37 (-4.84%)
NIO   22.66 (-4.75%)
AMD   110.71 (-0.38%)
CGC   7.23 (-1.77%)
MU   81.97 (+1.55%)
GE   89.32 (-1.96%)
T   24.25 (-8.42%)
F   19.91 (-0.35%)
DIS   133.60 (-2.13%)
AMC   15.94 (-0.50%)
PFE   53.01 (+0.89%)
ACB   4.06 (-3.56%)
BA   194.27 (-4.82%)
NASDAQ:CUR

Neuralstem Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$1.12
+0.03 (+2.75%)
(As of 01/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.08
$1.14
50-Day Range
$0.67
$1.52
52-Week Range
$1.10
$13.78
Volume
43,321 shs
Average Volume
236,278 shs
Market Capitalization
$2.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.81

Receive CUR News and Ratings via Email

Sign-up to receive the latest news and ratings for Neuralstem and its competitors with MarketBeat's FREE daily newsletter.


Neuralstem logo

About Neuralstem

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Headlines

GK Software Announces Availability on AWS - Yahoo Finance UK
December 14, 2021 |  uk.finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CUR
Fax
N/A
Employees
6
Year Founded
N/A

Sales & Book Value

Annual Sales
$260 thousand
Book Value
$6.64 per share

Profitability

Net Income
$-4.93 million
Net Margins
-39,417.64%
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$2.35 million
Optionable
Optionable

Company Calendar

Last Earnings
8/14/2019
Today
1/26/2022

MarketRank

Overall MarketRank

1.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Neuralstem (NASDAQ:CUR) Frequently Asked Questions

How were Neuralstem's earnings last quarter?

Neuralstem, Inc. (NASDAQ:CUR) announced its quarterly earnings results on Wednesday, August, 14th. The company reported ($1.45) EPS for the quarter. The firm had revenue of $0.01 million for the quarter. Neuralstem had a negative net margin of 39,417.64% and a negative trailing twelve-month return on equity of 170.51%.
View Neuralstem's earnings history
.

When did Neuralstem's stock split? How did Neuralstem's stock split work?

Neuralstem's stock reverse split on Thursday, July 18th 2019. The 1-20 reverse split was announced on Tuesday, July 16th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 17th 2019. An investor that had 100 shares of Neuralstem stock prior to the reverse split would have 5 shares after the split.

Who are Neuralstem's key executives?

Neuralstem's management team includes the following people:
  • Dr. Kenneth C. Carter, Exec. Chairman, CEO & Principal Financial Officer (Age 59)
  • Dr. Karl Y. Johe, Co-Founder (Age 59)
  • Dr. Thomas G. Hazel Ph.D., Sr. VP of Research
  • Dr. David P. Recker, Chief Medical Officer (Age 61)

What other stocks do shareholders of Neuralstem own?

What is Neuralstem's stock symbol?

Neuralstem trades on the NASDAQ under the ticker symbol "CUR."

What is Neuralstem's stock price today?

One share of CUR stock can currently be purchased for approximately $1.12.

How much money does Neuralstem make?

Neuralstem has a market capitalization of $2.35 million and generates $260 thousand in revenue each year.

How many employees does Neuralstem have?

Neuralstem employs 6 workers across the globe.

What is Neuralstem's official website?

The official website for Neuralstem is www.neuralstem.com.

Where are Neuralstem's headquarters?

Neuralstem is headquartered at 20271 Goldenrod Lane, Germantown MD, 20876.

How can I contact Neuralstem?

Neuralstem's mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The company can be reached via phone at 301-366-4841 or via email at [email protected].


This page was last updated on 1/26/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.